Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neurofibroma × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 44 Carcinoma, Renal Cell 25 Neoplasm Metastasis 15 Neoplasms 13 Kidney Neoplasms 11 Neuroendocrine Tumors 10 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Melanoma 6 Lymphoma 6 Tuberous Sclerosis 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Glioma 4 Colorectal Neoplasms 4 Carcinoma, Hepatocellular 4 Astrocytoma 4 Urinary Bladder Neoplasms 3 Stomach Neoplasms 3 Neurofibromatosis 2 3

Interventions

mirdametinib 2 tipifarnib 1 peginterferon alfa-2b 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Photochemotherapy 1 Mn-PyC3A 1 Everolimus 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02332902 2023-12-20

DCLNF1

The University of Texas Health Science Center, Houston

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡